IGBA Calls on all Stakeholders to Join the Biosimilars Movement on Advancing Access

1 November 2021

Digitalisation the key to efficient EU pharmaceutical regulation and easing of localised drug shortages

27 October 2021

“Digitalisation the key to efficient EU pharmaceutical regulation and easing […]

“Central Role For Industry Beckons As Europe Rebuilds After COVID” – Interview to Rebecca Guntern

25 October 2021

Generics And Biosimilars Must Become A Central Policy Pillar, Says […]

EU Industry Welcomes New Schengen Strategy’s Green Lanes

4 June 2021

“EU Industry Welcomes New Schengen Strategy’s Green Lanes” Read more

Opinion piece by Christoph Stoller for Friends of Europe

3 June 2021

“Too much at stake in the EU pharma strategy to […]

EU Industry Welcomes New Schengen Strategy’s Green Lanes

7 April 2021

Am fost foarte mândru de eforturile industriei noastre de a uni și a pune interesul pacienților absolut pe primul loc în timpul acestei crize

5 October 2020

Interviu cu Adrian van den Hoven, director general Medicines for Europe  […]

Practical measures are paramount for robust medicines manufacturing

9 September 2020

Interview: Medicines for Europe Reports on EU Biosimilar Success

27 July 2020

The Center for Biosimilars® (CfB) spoke with Adrian van den Hoven, […]

Christoph Stoller and Adrian van den Hoven interviewed by PharmaBoardroom

17 July 2020

In the wake of the publication of Medicines for Europe’s Lessons […]